AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28248037 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy (PNL)
Number of subjects: 100
Study 28248037 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lithotripsy (ESWL-URS)
Number of subjects: 100
Study 28248037 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 100
Study 25909311 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion with hemoglobin concentrations maintained above 9.0 g/dL (Group Hb9)
Number of subjects: 46
Study 25909311 — intervention group
Group type: COMPARATOR
Intervention: Withholding transfusion unless hemoglobin fell below 7.0 g/dL (Group Hb7)
Number of subjects: 46
Study 23009800 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer simulation videogame for eight sessions within 12 weeks
Number of subjects: 41
Study 23009800 — intervention group
Group type: COMPARATOR
Intervention: Educational slides about treatment for AUD
Number of subjects: 41
Study 19919580 — intervention group
Group type: COMPARATOR
Intervention: Intrarectal lidocaine gel (10 ml of 2% lidocaine)
Number of subjects: 100
Study 19919580 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal block (20 ml 0.1% bupivacaine with 75 microg fentanyl)
Number of subjects: 100
Study 19042837 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mcg octreotide
Number of subjects: 10
Study 19042837 — intervention group
Group type: COMPARATOR
Intervention: 400 mcg hyoscine hydrobromide
Number of subjects: 10
Study 16878325 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP (cyclophosphamide, vincristine, doxorubicin, and prednisone)
Number of subjects: 363
Study 16878325 — intervention group
Group type: COMPARATOR
Intervention: MCP (mitoxantrone, chlorambucil, and prednisone)
Number of subjects: 363
Study 12547870 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral approach (counseling strategy)
Number of subjects: 340
Study 12547870 — intervention group
Group type: COMPARATOR
Intervention: Usual care treatment (control)
Number of subjects: 340
Study 10883420 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 2 mg intravenously
Number of subjects: 12
Study 10883420 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 2 mg orally
Number of subjects: 12
Study 10883420 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 4 mg orally
Number of subjects: 12
Study 10883420 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study 9535618 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic nitrate therapy
Number of subjects: 29
Study 9535618 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nitrate therapy)
Number of subjects: 29
Study 8267871 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Number of subjects: 70
Study 8267871 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 70
Study 8267871 — intervention group
Group type: COMPARATOR
Intervention: Both toothbrushes
Number of subjects: 70
Study 3910582 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 40
Study 3910582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29135482 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib
Number of subjects: 54
Study 29135482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 26684822 — intervention group
Group type: EXPERIMENTAL
Intervention: RPV/FTC/TDF
Number of subjects: 799
Study 26684822 — intervention group
Group type: COMPARATOR
Intervention: EFV/FTC/TDF
Number of subjects: 799
Study 23860749 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibrating orogastric tube insertion
Number of subjects: 60
Study 22355040 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg/100 ml)
Number of subjects: 59
Study 22355040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 20014118 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg/d
Number of subjects: 63
Study 20014118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 20014118 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (n = 3)
Number of subjects: 63
Study 20014118 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 63
Study 19116709 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium bromide 0.4 mg every 6 hours for 12 hours
Number of subjects: 13
Study 19116709 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine hydrobromide 0.5 mg every 6 hours for 12 hours
Number of subjects: 13
Study 19116709 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 13
Study 15686289 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) applied during walking
Number of subjects: 8
Study 15686289 — intervention group
Group type: COMPARATOR
Intervention: Walking without FES (phase A)
Number of subjects: 8
Study 15686289 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking with FES (phase B)
Number of subjects: 8
Study 12821477 — intervention group
Group type: EXPERIMENTAL
Intervention: Garenoxacin 100 mg
Number of subjects: 40
Study 12821477 — intervention group
Group type: EXPERIMENTAL
Intervention: Garenoxacin 1200 mg
Number of subjects: 40
Study 12821477 — intervention group
Group type: EXPERIMENTAL
Intervention: Garenoxacin (100 to 400 mg)
Number of subjects: 40
Study 12821477 — intervention group
Group type: EXPERIMENTAL
Intervention: Garenoxacin (400 mg and above)
Number of subjects: 40
Study 12821477 — intervention group
Group type: EXPERIMENTAL
Intervention: Garenoxacin (all doses)
Number of subjects: 40
Study 12821477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10370688 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatogastrostomy
Number of subjects: 23
Study 10370688 — intervention group
Group type: COMPARATOR
Intervention: Pancreatojejunostomy
Number of subjects: 23
Study 8934255 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling the amount of LH administered
Number of subjects: 80
Study 8934255 — intervention group
Group type: COMPARATOR
Intervention: Standard amount of LH administered
Number of subjects: 80
Study 1766100 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.05 mg.kg‐1), n = 6
Number of subjects: 19
Study 1766100 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg.kg‐1), n = 7
Number of subjects: 19
Study 1766100 — intervention group
Group type: COMPARATOR
Intervention: Saline/Placebo, n = 6
Number of subjects: 19
Study 6350615 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin for 5 days postoperatively
Number of subjects: 223
Study 6350615 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin for 10 days postoperatively
Number of subjects: 223
Study 6350615 — intervention group
Group type: COMPARATOR
Intervention: No postoperative antibiotics
Number of subjects: 223
Study 30714750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 66
Study 30714750 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied relaxation (AR)
Number of subjects: 66
Study 30714750 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirective therapy (ND)
Number of subjects: 66
Study 29172593 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral therapy (iCBT) program for health anxiety (n = 45)
Number of subjects: 86
Study 29172593 — intervention group
Group type: COMPARATOR
Intervention: Active psychoeducation control group (n = 41)
Number of subjects: 86
Study 26350992 — intervention group
Group type: EXPERIMENTAL
Intervention: Nongrooved incisions
Number of subjects: 52
Study 26350992 — intervention group
Group type: EXPERIMENTAL
Intervention: Grooved incisions
Number of subjects: 52
Study 26350992 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 24629303 — intervention group
Group type: EXPERIMENTAL
Intervention: Scripted verbal or written consent process (group I)
Number of subjects: 102
Study 24629303 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based, audiovisual presentation (group II)
Number of subjects: 102
Study 24629303 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (group I and group II)
Number of subjects: 102
Study 22001100 — intervention group
Group type: EXPERIMENTAL
Intervention: 70-W high-power Ho:YAG laser lithotripsy
Number of subjects: 273
Study 22001100 — intervention group
Group type: COMPARATOR
Intervention: 30-W low-power Ho:YAG laser lithotripsy
Number of subjects: 273
Study 20117707 — intervention group
Group type: EXPERIMENTAL
Intervention: Biaxial microincision phacoemulsification (<1.5 mm)
Number of subjects: 94
Study 20117707 — intervention group
Group type: COMPARATOR
Intervention: Coaxial small-incision phacoemulsification (2.8 mm)
Number of subjects: 94
Study 20117707 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 94
Study 17870048 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacryocystoplasty (Lacricath) and silicone intubation (Ritleng)
Number of subjects: 70
Study 17870048 — intervention group
Group type: COMPARATOR
Intervention: Silicone intubation alone
Number of subjects: 70
Study 15976999 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2 kinetics during repeated sprint exercise (RSE)
Number of subjects: 11
Study 12190656 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily
Number of subjects: 191
Study 12190656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 10652036 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 102
Study 10652036 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (N = 21)
Number of subjects: 102
Study 10652036 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (N = 11)
Number of subjects: 102
Study 10652036 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 102
Study 10652036 — intervention group
Group type: EXPERIMENTAL
Intervention: Macroalbuminuria group
Number of subjects: 102
Study 10652036 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 102
Study 8655928 — intervention group
Group type: EXPERIMENTAL
Intervention: D5W
Number of subjects: 12
Study 8655928 — intervention group
Group type: COMPARATOR
Intervention: 1/2NS
Number of subjects: 12
Study 1325889 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing soluble pyrophosphate
Number of subjects: 88
Study 1325889 — intervention group
Group type: COMPARATOR
Intervention: Control MFP dentifrice
Number of subjects: 88
Study 6832462 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg indobufen administered orally or by i.v. injection
Number of subjects: 12
Study 6832462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30216492 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolones
Number of subjects: 5148
Study 30216492 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 5148
Study 30216492 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 5148
Study 28758526 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Reading Fluency (ORF) slope
Number of subjects: 102
Study 27474232 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not enrolled on AAML0531 trial
Number of subjects: 0
Study 27474232 — intervention group
Group type: COMPARATOR
Intervention: Patients enrolled on AAML0531 trial
Number of subjects: 0
Study 27474232 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonenrollment
Number of subjects: 0
Study 27474232 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge
Number of subjects: 0
Study 25220196 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeland HHRI
Number of subjects: 32
Study 25220196 — intervention group
Group type: COMPARATOR
Intervention: Global C.A.P. HHRI
Number of subjects: 32
Study 25220196 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised HHRI
Number of subjects: 32
Study 25220196 — intervention group
Group type: COMPARATOR
Intervention: Nonrevised HHRI
Number of subjects: 32
Study 22038501 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy
Number of subjects: 112
Study 22038501 — intervention group
Group type: COMPARATOR
Intervention: Standard lymphadenectomy
Number of subjects: 112
Study 20307702 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program
Number of subjects: 185
Study 20307702 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 185
Study 18069601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioversion of atrial fibrillation
Number of subjects: 0
Study 18069601 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic therapies for stroke prevention
Number of subjects: 0
Study 18069601 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate control drugs (old and new)
Number of subjects: 0
Study 18069601 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical management of AF
Number of subjects: 0
Study 18069601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation of perivenous pulmonary circuits, ablation of the AV node, and implantation of a pacemaker
Number of subjects: 0
Study 16096180 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% or 0.1% tacrolimus ointment applied twice daily
Number of subjects: 9813
Study 12030342 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (3 mg/h infusion)
Number of subjects: 40
Study 12030342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12502274 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention including classroom-based curriculum, parent training, and home visits.
Number of subjects: 0
Study 12502274 — intervention group
Group type: COMPARATOR
Intervention: Matched control group (not specified what the control intervention was).
Number of subjects: 0
Study 12799953 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 90
Study 12799953 — intervention group
Group type: EXPERIMENTAL
Intervention: Butylscopolamine 20 mg
Number of subjects: 90
Study 12799953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 7516295 — intervention group
Group type: EXPERIMENTAL
Intervention: Human, recombinant GH (Genotropin, Kabi Pharmacia, Uppsala, Sweden) at a dosage of 0.1 IU/kg body weight per day
Number of subjects: 40
Study 7516295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7516295 — intervention group
Group type: EXPERIMENTAL
Intervention: Human, recombinant GH (Genotropin, Kabi Pharmacia, Uppsala, Sweden)
Number of subjects: 40
Study 2680176 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral photochemotherapy (PUVA) for 4 weeks
Number of subjects: 14
Study 2680176 — intervention group
Group type: COMPARATOR
Intervention: Control (covered skin)
Number of subjects: 14
Study 769721 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 31
Study 769721 — intervention group
Group type: EXPERIMENTAL
Intervention: Levoamphetamine
Number of subjects: 31
Study 769721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 769721 — intervention group
Group type: EXPERIMENTAL
Intervention: Both (Levoamphetamine and Dextroamphetamine)
Number of subjects: 31
Study 7305656 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride therapy after surgery
Number of subjects: 15
Study 7305656 — intervention group
Group type: COMPARATOR
Intervention: No propranolol hydrochloride therapy after surgery
Number of subjects: 15
Study 31128957 — intervention group
Group type: EXPERIMENTAL
Intervention: Dating Matters
Number of subjects: 2349
Study 31128957 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 2349
Study 28975661 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance and Impact Training (HiRIT)
Number of subjects: 101
Study 28975661 — intervention group
Group type: COMPARATOR
Intervention: Control (home-based, low-intensity exercise program)
Number of subjects: 101
Study 26843131 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR imaging after systemic indocyanine green (ICG)
Number of subjects: 12
Study 26843131 — intervention group
Group type: COMPARATOR
Intervention: Traditional margin assessment
Number of subjects: 12
Study 26843131 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR imaging after systemic ICG
Number of subjects: 12
Study 25380675 — intervention group
Group type: EXPERIMENTAL
Intervention: IRX (45 min of cycling)
Number of subjects: 17
Study 25380675 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 17
Study 25380675 — intervention group
Group type: COMPARATOR
Intervention: IRC (control trial without physical activity)
Number of subjects: 17
Study 22175695 — intervention group
Group type: EXPERIMENTAL
Intervention: Water treatment and hygiene promotion (WT & HP)
Number of subjects: 0
Study 22175695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanitation improvement in combination with WT & HP
Number of subjects: 0
Study 22175695 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 20074412 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced DOTS (DOTS-A)
Number of subjects: 650
Study 20074412 — intervention group
Group type: COMPARATOR
Intervention: Routine DOTS
Number of subjects: 650
Study 18948639 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathy in the cranial field, myofascial release, or both (OMT)
Number of subjects: 55
Study 18948639 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 55
Study 18948639 — intervention group
Group type: COMPARATOR
Intervention: Control (nontherapeutic attention)
Number of subjects: 55
Study 16211739 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 0.1 mg
Number of subjects: 100
Study 16211739 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 0.2 mg
Number of subjects: 100
Study 16211739 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 0.3 mg
Number of subjects: 100
Study 16211739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 16211739 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (all doses)
Number of subjects: 100
Study 12423702 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogens
Number of subjects: 60
Study 12423702 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol‐17‐beta with progestins
Number of subjects: 60
Study 12423702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12423702 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in androstenedione levels
Number of subjects: 60
Study 12423702 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum concentration of estradiol‐17‐beta
Number of subjects: 60
Study 10606212 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium HMB supplementation (3 to 6 g x d(‐1))
Number of subjects: 40
Study 8947787 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 27
Study 8947787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 1747493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg tid)
Number of subjects: 48
Study 1747493 — intervention group
Group type: EXPERIMENTAL
Intervention: Clebopride (0.5 mg tid)
Number of subjects: 48
Study 7107939 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotapes depicting alcoholics with varying race and socioeconomic status
Number of subjects: 40
Study 31166987 — intervention group
Group type: EXPERIMENTAL
Intervention: 15, 30 or 60 μg/strain of quadrivalent virus-like particle (QVLP) vaccine
Number of subjects: 2
Study 31166987 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 or 15 μg/strain of QVLP with alum
Number of subjects: 2
Study 31166987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 31166987 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg QVLP vaccine
Number of subjects: 2
Study 29257792 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed high volume and high intensity (MP) resistance training program (10-12 reps at 65%-70% of 1RM for lower body; HI protocol for upper body)
Number of subjects: 20
Study 29257792 — intervention group
Group type: COMPARATOR
Intervention: High intensity (HI) resistance training program (4-5 reps at 88%-90% of 1RM for both upper and lower body)
Number of subjects: 20
Study 26565438 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Constraint Induced Movement Therapy (hCIMT)
Number of subjects: 44
Study 26565438 — intervention group
Group type: COMPARATOR
Intervention: Distributed individual occupational therapy (OT)
Number of subjects: 44
Study 23852397 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus weekly split-dose cisplatin (SWP)
Number of subjects: 37
Study 23852397 — intervention group
Group type: COMPARATOR
Intervention: S-1 plus standard-dose cisplatin (SP)
Number of subjects: 37
Study 23065071 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 17500
Study 23065071 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tricyclic antidepressants
Number of subjects: 17500
Study 20391513 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg
Number of subjects: 56
Study 20391513 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 180 mg
Number of subjects: 56
Study 20391513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 17708846 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine treatment group (0.4 g/kg per day for 7 days)
Number of subjects: 44
Study 17708846 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard PN and EN without glutamine)
Number of subjects: 44
Study 15560969 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting risperidone
Number of subjects: 214
Study 15560969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 12776266 — intervention group
Group type: EXPERIMENTAL
Intervention: Long daily regimen (prednisolone 60 mg/m2 for 6 weeks, then 40 mg/m2 alternate-day for 6 weeks)
Number of subjects: 73
Study 12776266 — intervention group
Group type: EXPERIMENTAL
Intervention: Long alternate-day regimen (prednisolone 60 mg/m2 for 4 weeks, then 60 mg/m2 alternate-day for 4 weeks, tapering by 10 mg/m2 every 4 weeks)
Number of subjects: 73